📊 HCWB Key Takeaways
Is HCW Biologics Inc. (HCWB) a Good Investment?
HCW Biologics is in acute financial distress with essentially zero revenue ($54.2K), unsustainable cash burn of $13.4M annually, and only $2M in remaining cash providing approximately 1-2 months of runway. The current ratio of 0.11x indicates severe liquidity crisis and imminent solvency risk.
Fundamentals indicate acute financial stress: revenue collapsed 97.9% YoY and operations continue to burn significant cash, driving extreme negative margins. Liquidity is critically weak (current ratio 0.11x; cash $1.95M) against ongoing losses, implying a high probability of near‑term financing needs and dilution. While net loss improved YoY and there is no long‑term debt, the current runway and growth quality are insufficient to support a constructive view.
Why Buy HCW Biologics Inc. Stock? HCWB Key Strengths
- Zero long-term debt reduces leverage risk
- Net loss improved 64.3% YoY indicating cost reduction efforts
- Gross margin of 20% suggests potential profitability if revenue materializes
- No long-term debt, reducing fixed interest burden
- Net loss and EPS improved YoY, suggesting cost control
- Capex-light model (zero capex) preserves cash for core ops
HCWB Stock Risks: HCW Biologics Inc. Investment Risks
- Revenue collapsed 97.9% YoY to only $54.2K, indicating commercial failure or operations suspension
- Current ratio of 0.11x signals critical liquidity crisis and potential insolvency within weeks
- Annual operating cash burn of $13.4M against $2M cash balance indicates bankruptcy risk without immediate financing
- Shareholder equity of $2.8M represents minimal buffer; dilution evident from -$10.63 EPS
- Zero insider Form 4 filings in 90 days suggests management has no confidence in recovery
- Severe liquidity shortfall (current ratio 0.11x; low cash)
- Large ongoing cash burn and negative FCF imply financing/dilution risk
- Revenue collapse (-97.9% YoY) with extreme negative margins
Key Metrics to Watch
- Monthly cash balance and burn rate to determine bankruptcy timeline
- Revenue trajectory and any new financing announcements
- Changes in current ratio and working capital position indicating structural improvement
- Operating cash flow (quarterly cash burn)
- Cash & equivalents / current ratio (liquidity runway)
HCW Biologics Inc. (HCWB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
HCWB Profit Margin, ROE & Profitability Analysis
HCWB vs Healthcare Sector: How HCW Biologics Inc. Compares
How HCW Biologics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is HCW Biologics Inc. Stock Overvalued? HCWB Valuation Analysis 2026
Based on fundamental analysis, HCW Biologics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
HCW Biologics Inc. Balance Sheet: HCWB Debt, Cash & Liquidity
HCWB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: HCW Biologics Inc.'s revenue has declined by 37% over the 5-year period, indicating business contraction. The most recent EPS of $-30.96 indicates the company is currently unprofitable.
HCWB Revenue Growth, EPS Growth & YoY Performance
HCWB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $15.6K | -$1.9M | $-2.02 |
| Q2 2025 | $6.6K | -$1.9M | $-6.79 |
| Q1 2025 | $5.1K | -$2.2M | $-0.05 |
| Q3 2024 | $426.4K | -$3.9M | $-0.10 |
| Q2 2024 | $618.9K | -$4.3M | $-0.12 |
| Q1 2024 | $41.9K | -$5.1M | $-0.14 |
| Q3 2023 | $853.1K | -$2.1M | $-0.11 |
| Q2 2023 | $454.0K | -$2.1M | $-0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
HCW Biologics Inc. Dividends, Buybacks & Capital Allocation
HCWB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for HCW Biologics Inc. (CIK: 0001828673)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HCWB
What is the AI rating for HCWB?
HCW Biologics Inc. (HCWB) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 93% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HCWB's key strengths?
Claude: Zero long-term debt reduces leverage risk. Net loss improved 64.3% YoY indicating cost reduction efforts. ChatGPT: No long-term debt, reducing fixed interest burden. Net loss and EPS improved YoY, suggesting cost control.
What are the risks of investing in HCWB?
Claude: Revenue collapsed 97.9% YoY to only $54.2K, indicating commercial failure or operations suspension. Current ratio of 0.11x signals critical liquidity crisis and potential insolvency within weeks. ChatGPT: Severe liquidity shortfall (current ratio 0.11x; low cash). Large ongoing cash burn and negative FCF imply financing/dilution risk.
What is HCWB's revenue and growth?
HCW Biologics Inc. reported revenue of $54.2K.
Does HCWB pay dividends?
HCW Biologics Inc. does not currently pay dividends.
Where can I find HCWB SEC filings?
Official SEC filings for HCW Biologics Inc. (CIK: 0001828673) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HCWB's EPS?
HCW Biologics Inc. has a diluted EPS of $-10.63.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HCWB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, HCW Biologics Inc. has a STRONG SELL rating with 93% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HCWB stock overvalued or undervalued?
Valuation metrics for HCWB: ROE of -287.9% (sector avg: 15%), net margin of -14,677.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy HCWB stock in 2026?
Our dual AI analysis gives HCW Biologics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HCWB's free cash flow?
HCW Biologics Inc.'s operating cash flow is $-13.4M, with capital expenditures of $0.0. FCF margin is -24,693.2%.
How does HCWB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -14,677.1% (avg: 12%), ROE -287.9% (avg: 15%), current ratio 0.11 (avg: 2).